Immunologically active autoantigens: The role of Toll-like receptors in the development of chronic inflammatory disease

Annual Review of Immunology

Volumn 25, Issue , 2007, Pages 419-441

  Marshak Rothstein, Ann ^a   Rifkin, Ian R ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoantibodies; Systemic autoimmune disease; Toll like receptor 7; Toll like receptor 9

Indexed keywords

AUTOANTIGEN; BACTERIAL DNA; BACTERIAL RNA; CHEMOKINE; CYTOKINE; GLYCOSAMINOGLYCAN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; VIRUS RNA;

APOPTOSIS; AUTOIMMUNITY; CELL DAMAGE; CHRONIC INFLAMMATION; GENE OVEREXPRESSION; HUMAN; IMMUNE SYSTEM; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; APOPTOSIS; AUTOANTIGENS; AUTOIMMUNE DISEASES; CHRONIC DISEASE; DNA; DNA-BINDING PROTEINS; EPITOPES; HUMANS; INFLAMMATION; RNA; TOLL-LIKE RECEPTORS;

EID: 34247891509     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.22.012703.104514     Document Type: Review

References (125)

1. Tan EM, Chan EKL, Sullivan KF, Rubin RL. 1988. Antinuclear antibodies (ANAs): diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin. Immunol. Immunopathol. 47:121-41
2. Plotz PH. 2003. The autoantibody repertoire: searching for order. Nat. Rev. Immunol. 3:73-78
3. Phillips PE. 1975. The virus hypothesis in systemic lupus erythematosus. Ann. Int. Med. 83:709-15
4. Denman AM. 2000. Systemic lupus erythematosus - is a viral etiology a credible hypothesis? J. Infect. 40:229-33
5. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. 2005. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat. Med. 11:85-89
6. Casciola-Rosen LA, Anhalt G, Rosen A. 1994. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 179:1317-30
7. Maldonado MA, Kakkanaiah V, MacDonald GC, Chen F, Reap EA, et al. 1999. The role of environmental antigens in the spontaneous development of autoimmunity in MRL-lpr mice. J. Immunol. 162:6322-30
8. Casciola-Rosen LA, Andrade F, Ulanet D, Wong WB, Rosen A. 1999. Cleavage by granzyme B is strongly predictive of autoantigen status: implication for initiation of autoimmunity. J. Exp. Med. 190:815-25
9. Utz PJ, Gensler TJ, Anderson P. 2000. Death, autoantigen modifications, and tolerance. Arthritis Res. 2:101-14
10. Anderton SM. 2004. Post-translational modifications of self antigens: implications for autoimmunity. Curr. Opin. Immunol. 16:753-58
11. Hall JC, Casciola-Rosen L, Rosen A. 2004. Altered structure of autoantigens during apoptosis. Rheum. Dis. Clin. N. Am. 30:455-71
12. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H. 2002. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct compartments. Eur. J. Immunol. 32:1958-68
13. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, et al. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-45
14. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. 2003. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 198:513-20
15. Krieg AM. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:709-60
16. Krieg AM. 2006. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5:471-84
17. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, et al. 2004. TLR7: a new sensor of viral infection. Proc. Natl. Acad. Sci. USA 101:6835-36
18. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529-31
19. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, et al. 2004. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303:1526-29
20. Vollmer J, Tluk S, Schmitz C, Jurk M, Forsbach A, et al. 2005. Autoantigen binding sites within small nuclear RNAs induce innate immunity through Toll-like receptors 7 and 8. J. Exp. Med. 202:1575-85
21. Kariko K, Buckstein M, Ni H, Weissman D. 2005. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23:165-75
22. Palucka AK, Banchereau J, Blanco P, Pascual V. 2002. The interplay of dendritic cell subsets in systemic lupus erythematosus. Immunol. Cell Biol. 80:484-88
23. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. 2003. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19:225-34
24. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, et al. 2005. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 174:1259-68
25. Shlomchik MJ, Zharhary D, Camper S, Saunders T, Weigert M. 1993. A rheumatoid factor transgenic mouse model of autoantibody regulation. Int. Immunol. 5:1329-41
26. Jacobson BA, Sharon J, Shan H, Shlomchik M, Weigert MG, Marshak-Rothstein A. 1994. An isotype switched and somatically mutated rheumatoid factor clone isolated from a MRL-lpr/lpr mouse exhibits limited intraclonal affinity maturation. J. Immunol. 152:4489-99
27. Hannum LG, Ni D, Haberman AM, Weigert MG, Shlomchik MJ. 1996. A disease-related rheumatoid factor autoantibody is not tolerized in a normal mouse: implications for the origins of autoantibodies in autoimmune disease. J. Exp. Med. 184:1269-78
28. Wang H, Shlomchik MJ. 1999. Autoantigen-specific B cell activation in Fas-deficient rheumatoid factor immunoglobulin transgenic mice. J. Exp. Med. 190:639-49
29. William J, Euler C, Leadbetter EA, Marshak-Rothstein A, Shlomchik MJ. 2003. Visualizing the onset and evolution of an autoantibody response in systemic autoimmunity. J. Immunol. 174:6872-78
30. Rifkin IR, Leadbetter EA, Beaudette BC, Kiani C, Monestier M, et al. 2000. Immune complexes present in the sera of autoimmune mice activate rheumatoid factor B cells. J. Immunol. 165:1626-33
31. Leadbetter EA, Rifkin IR, Hohlbaum AH, Beaudette B, Shlomchik MJ, Marshak-Rothstein A. 2002. Chromatin-IgG complexes activate autoreactive B cells by dual engagement of sIgM and Toll-like receptors. Nature 416:603-7
32. Busconi L, Lau CM, Tabor AS, Uccellini MS, Ruhe Z, et al. 2006. DNA and RNA autoantigens as autoadjuvants. J. Endotoxin Res. 12:379-84
33. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, et al. 2005. RNA-associated autoantigens activate B cells by combined BCR/Toll-like receptor 7 engagement. J. Exp. Med. 202:1171-77
34. Bekeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, et al. 2005. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 174:4043-50
35. Vallin H, Blomberg S, Alm GV, Cederblad B, Ronnblom L. 1999. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-α (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clin. Exp. Immunol. 115:196-202
36. Batteux F, Palmer P, Daeron M, Weill B, Lebon P. 1999. FCγRII (CD32)-dependent induction of interferon-α by serum from patients with lupus erythematosus. Eur. Cytokine Netw. 10:509-14
37. Ronnblom L, Alm GV. 2001. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol. 22:427-31
38. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. 2004. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic orlate apoptotic cells and lupus IgG. Arthritis Rheum. 50:1861-72
39. Magnusson M, Magnusson S, Vallin H, Ronnblom L, Alm GV. 2001. Importance of CpG dinucleotides in activation of natural IFN-α-producing cells by a lupus-related oligodeoxynucleotide. Scand. J. Immunol. 54:543-50
40. Lovgren T, Eloranta ML, Kastner B, Wahren-Herlenius M, Alm GV, Ronnblom L. 2006. Induction of interferon-α by immune complexes or liposomes containing systemic lupus erythematosus and Sjogren's syndrome autoantigen-associated RNA. Arthritis Rheum. 54:1917-27
41. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, et al. 2005. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202:1131-39
42. Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L. 2003. FcγRIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG. J. Immunol. 171:3296-302
43. Savarese E, Chae OW, Trowitzsch S, Weber G, Kastner B, et al. 2006. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 107:3229-34
44. Liu YJ. 2005. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23:275-306
45. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. 2005. Type I interferons (α/β) in immunity and autoimmunity. Annu. Rev. Immunol. 23:307-36
46. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, et al. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100:2610-15
47. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, et al. 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 17:711-23
48. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, et al. 2005. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 76:528-37
49. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, et al. 2006. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat. Genet. 38:550-55
50. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. 2005. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115:407-17
51. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. 2004. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199:1631-40
52. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, et al. 1999. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189:371-80
53. Fernandez N, Renedo M, Garcia-Rodriguez C, Sanchez Crespo M. 2002. Activation of monoqrtic cells through Fcγ receptors induces the expression of macrophage-inflammatory protein (MIP)-1α, MIP-1β, and RANTES. J. Immunol. 169:3321-28
54. Zhang W, Voice J, Lachmann PJ. 1995. A systematic study of neutrophil degranulation and respiratory burst in vitro by defined immune complexes. Clin. Exp. Immunol. 1995:507-14
55. Yoneyama M, Rikuch M, Natsukawa T, Shinobu N, Imaizumi T, et al. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5:730-37
56. Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, et al. 2005. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol. 175:5260-68
57. Ishii KJ, Coban C, Kato H, Takahashi K, Torii Y, et al. 2006. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat. Immunol. 7:40-48
58. Bolland S, Ravetch JV. 2000. Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity 13:277-85
59. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV. 2006. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J. Exp. Med. 203:553-61
60. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. 2005. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202:312-31
61. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. 2006. TLR7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25:417-28
62. Wu X, Peng SL. 2006. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum. 54:336-42
63. Lartigue A, Courville P, Auquit I, Francois A, Arnoult C, et al. 2006. Role of TLR9 in antinucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus. J. Immunol. 177:1349-54
64. Yu P, Wellmann U, Kunder S, Quintanilla-Martinez L, Jennen L, et al. 2006. Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE. Int. Immunol. 18:1211-19
65. Berland R, Fernandez L, Kari E, Han JH, Lomakin I, et al. 2006. TLR7-dependent loss of B cell tolerance in pathogenic autoantibody knock-in mice. Immunity 25:429-40
66. Murphy ED, Roths JB. 1979. A Y chromosome associated factor in strain BXSB producing accelerated autoimmunity and lymphoproliferation. Arthritis Rheum. 22:1188-94
67. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. 2006. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312:1669-72
68. Subramanian S, Tus K, Li QZ, Wang A, Tian XH, et al. 2006. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl. Acad. Sci. USA 103:9970-75
69. -/- mice. J. Exp. Med. 195:1167-74
70. Morel L, Croker BP, Blenman KR, Mohan C, Huang G, et al. 2000. Genetic reconstitution of systemic lupus erythematosus immunopathology with polygenic murine strains. Proc. Natl. Acad. Sci. USA 97:6670-75
71. Moll T, Martinez-Soria E, Santiago-Raber ML, Amano H, Pihlgren-Bosch M, et al. 2005. Differential activation of antierythrocyte and anti-DNA autoreactive B lymphocytes by the Yaa mutation. J. Immunol. 174:702-9
72. Lian ZX, Kikuchi K, Yang GX, Ansari AA, Ikehara S, Gershwin ME. 2004. Expansion of bone marrow IFN-α-producing dendritic cells in New Zealand Black (NZB) mice: high level expression of TLR9 and secretion of IFN-α in NZB bone marrow. J. Immunol. 173:5283-89
73. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, et al. 2003. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197:777-88
74. Quintana FJ, Cohen IR. 2005. Heat shock proteins as endogenous adjuvants in sterile and septic inflammation. J. Immunol. 175:2777-82
75. Panjwani NN, Popova L, Srivastava PK. 2002. Heat shock proteins gp96 and hsp70 activate the release of nitric oxide by APCs. J. Immunol. 168:2997-3003
76. Liu B, Dai J, Zheng H, Stoilova D, Sun S, Li Z. 2003. Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc. Natl. Acad. Sci. USA 100:15824-29
77. Dieude M, Senecal JL, Raymond Y. 2004. Induction of endothelial cell apoptosis by heat-shock protein 60-reactive antibodies from antiendothelial cell autoantibody-positive systemic lupus erythematosus patients. Arthritis Rheum. 50:3221-31
78. Minota S, Koyasu S, Yahara I, Winfield J. 1988. Autoantibodies to the heat-shock protein hsp90 in systemic lupus erythematosus. J. Clin. Invest. 81:106-9
79. Stephanou A, Latchman DS, Isenberg DA. 1998. The regulation of heat shock proteins and their role in systemic lupus erythematosus. Semin. Arthritis Rheum. 28:155-62
80. Basu S, Binder RJ, Ramalingam T, Srivastava PK. 2001. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14:303-13
81. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, et al. 2003. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22:5551-60
82. Ulloa L, Messmer D. 2006. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev. 17:189-201
83. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, et al. 2005. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand. J. Immunol. 61:1-9
84. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, et al. 2004. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279:7370-77
85. Taylor KR, Gallo RL. 2006. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J. 20:9-22
86. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. 2002. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4.7 Immunol. 168:5233-39
87. Renaudineau Y, Revelen R, Dueymes M, Levy Y, Youinou P. 2002. Autoantibodies to heparan sulfate proteoglycans. Autoimmun. Rev. 1:305-12
88. Taylor KR, Trowbridge JM, Rudisill JA, Termeer CC, Simon JC, Gallo RL. 2004. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J. Biol. Chem. 279:17079-84
89. Jiang D, Liang J, Fan J, Yu S, Chen S, et al. 2005. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat. Med. 11:1173-79
90. Kahaly G, Hansen CE, Stover C, Beyer J, Otto E. 1993. Glycosaminoglycan antibodies in endocrine opthalmopathy. Horm. Metab. Res. 25:637-39
91. Faaber P, van den Bersselaar LA, van de Putte LB, van den Berg WB. 1989. Immune complex formation between IgM rheumatoid factor and IgG generated by hyaluronic acid. Arthritis Rheum. 32:1521-27
92. Siegelman MH, DeGrendele HC, Estess P. 1999. Activation and interaction of CD44 and hyaluronan in immunological systems. J. Leukoc. Biol. 66:315-21
93. Quinn MT, Parthasarathy S, Steinberg D. 1988. Lysophosphatidylcholine: achemotactic factor for human monocytes and its potential role in atherogenesis. Proc. Natl. Acad. Sci. USA 85:2805-909
94. 2 activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. J. Exp. Med. 196:655-65
95. Lauber K, Blumenthal SG, Waibel M, Wesselborg S. 2004. Clearance of apoptotic cells: getting rid of the corpses. Mol. Cell 14:277-87
96. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. 1997. Immunosuppressive effects of apoptotic cells. Nature 390:350-51
97. Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, et al. 1998. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 19:56-59
98. Bickerstaff MCM, Botto M, Hutchinson WL, Herbert J, Tennent GA, et al. 1999. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat. Med. 5:694-97
99. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Moroy T. 2000. Features of systemic lupus erythematosis in DNase1-deficient mice. Nat. Genet. 25:177-80
100. Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, et al. 2002. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J. Exp. Med. 196:135-40
101. Hanayama R, Tanaka M, Miyasaka K, Aozasa K, Koike M, et al. 2004. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 304:1147-50
102. Chang MK, Binder CJ, Miller YI, Subbanagounder G, Silverman GJ, et al. 2004. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J. Exp. Med. 200:1359-70
103. Hansson GK, Libby P. 2006. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6:508-19
104. Walton KA, Hsieh X, Gharavi N, Wang S, Wang G, et al. 2003. Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3- phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J. Biol. Chem. 278:29661-66
105. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. 2003. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J. Biol. Chem. 278:1561-68
106. Shaw PX, Goodyear CS, Chang MK, Witztum JL, Silverman GJ. 2003. The autoreactivity of antiphosphorylcholine antibodies for atherosclerosis- associated neo-antigens and apoptotic cells. J. Immunol. 170:6151-57
107. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S. 2005. Macrophage receptors and immune recognition. Annu. Rev. Immunol. 23:910-44
108. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, et al. 2003. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349:2407-15
109. Aprahamian T, Rifkin I, Bonegio R, Hugel B, Freyssinet JM, et al. 2004. Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J. Exp. Med. 199:1-12
110. Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, et al. 2001. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104:1887-93
111. Howard OM, Dong HF, Yang D, Raben N, Nagaraju K, et al. 2002. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J. Exp. Med. 196:781-91
112. Deleted in proof
113. Vigilanti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. 2003. Activation of autoreactive B cells by CpG dsDNA. Immunity 19:837-47
114. Fields ML, Metzgar MH, Hondowicz BD, Kang SA, Alexander ST, et al. 2 006. Exogenous and endogenous TLR ligands activate antichromatin and polyreactive B cells. J. Immunol. 176:6491-502
115. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, et al. 2001. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194:863-69
116. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. 2001. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol. 31:3388-93
117. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, et al. 2002. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168:4531-37
118. Asselin-Paturel C, Brizard G, Chemin K, Boonstra A, O'Garra A, et al. 2005. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J. Exp. Med. 210:1157-67
119. + DC correlates with unresponsiveness to imidazoquinolines. Eur. J. Immunol. 33:827-33
120. Uchijima M, Nagata T, Aoshi T, Koide Y. 2005. IFN-γ overcomes low responsiveness of myeloid dendritic cells to CpG DNA. Immunol. Cell Biol. 83:92-95
121. Matsushima H, Yamada N, Matsue H, Shimada S. 2004. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J. Immunol. 173:531-41
122. Mitsui H, Watanabe T, Saeki H, Mori K, Fujita H, et al. 2004. Differential expression and function of Toll-like receptors in Langerhans cells: comparison with splenic dendritic cells. J. Invest. Dermatol. 122:95-102
123. Iwasaki A, Medzhitov R. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5:987-95
124. Funitaka H, Means TK, Luster AD. 2003. Toll-like receptors stimulate human neutrophil function. Blood 102:2660-69
125. Aslam R, Speck ER, Kim M, Crow AR, Bang KW, et al. 2006. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-α production in vivo. Blood 107:637-41